Driving Home: U.S. Auto Reshoring
A new U.S.-Japan trade deal lowers tariffs on Japanese auto imports, creating a cost disadvantage for Detroit automakers reliant on North American manufacturing. This theme focuses on U.S. companies poised to benefit as automakers move production back to the U.S. to mitigate these new tariff-related costs.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
A new U.S.-Japan trade deal has created a cost imbalance for American automakers by lowering tariffs on Japanese imports while keeping higher rates on North American production. This policy shift is driving a strategic response: automakers are incentivized to move manufacturing back to the U.S. to regain competitive footing and protect their market share.
What You Need to Know
This group focuses on companies that support domestic automotive production, including parts manufacturers, industrial automation specialists, and supply chain firms. These businesses are positioned to benefit from increased investment as major automakers pivot toward U.S.-based operations to mitigate the new tariff-related cost pressures.
Why These Stocks
These companies were handpicked by professional analysts as integral players in the domestic automotive ecosystem. They represent firms that could see increased demand and investment as the auto industry undergoes this potential cyclical shift toward reshoring manufacturing operations back to American soil.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+13.98%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 13.98% over the next year.
Stocks Rated Buy by Analysts
12 of 15 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 2.3% return last month.
Why You'll Want to Watch These Stocks
Manufacturing Renaissance
Trade policy shifts are creating a powerful incentive for automakers to bring production back home. This could spark a new wave of investment in U.S. manufacturing infrastructure and the companies that support it.
Policy-Driven Opportunity
The tariff imbalance between Japanese imports and North American production creates an immediate competitive pressure. Companies positioned to benefit from reshoring could see accelerated growth as automakers adapt to this new reality.
Supply Chain Advantage
As major automakers pivot toward domestic operations, the firms that can efficiently support U.S.-based production stand to gain significant market share. This represents a tactical opportunity tied to a specific trade policy shift.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.